Cefepime Hydrochloride/Enmetazobactam

N/A

Report date: 2026/04/16 20:00:17
NMEQIDP

Base Information

Drug NameCefepime Hydrochloride/Enmetazobactam
Drug Alias NameCefepime Hydrochloride/AAI-101AAI-101/cefepimeCefepime/AAI-101FEP/AAI-101Cefepime hydrochloride monohydrate/enmetazobactam +[12] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Cephalosporins antibiotics
Mechanisms of ActionBeta Lactamase inhibitorsCell wall inhibitorsBacterial penicillin-binding protein inhibitors
TargetsBacterial penicillin-binding proteinBeta Lactamase
Therapy Area/IndicationsHospital-acquired pneumoniaPyelonephritisUrinary Tract Infections +[4] 
Global Approved IndicationsHospital-acquired pneumoniaPyelonephritisUrinary Tract Infections +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/02/22
Country/TerritoryCzechiaBulgariaUnited States +[22] 
CombinationsYes Cefepime HydrochlorideEnmetazobactam
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAllecra Therapeutics GmbH
China Registration ClassN/A

Develop Information

Active CompaniesAdvanz Pharma LtdYangtze River Pharmaceutical Group Shanghai Hai-Ni Pharmaceutical Co LtdAllecra
Inactive CompaniesOrchid Pharma LtdAllecra Therapeutics GmbH
Active IndicationsHospital-acquired pneumoniaPyelonephritisUrinary Tract Infections +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A